NIVFW
Income statement / Annual
Last year (2024), NewGenIvf Group Limited's total revenue was $5.43 M,
an increase of 5.79% from the previous year.
In 2024, NewGenIvf Group Limited's net income was -$524.64 K.
See NewGenIvf Group Limited,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
Operating Revenue |
$5.43 M |
$5.14 M |
$5.94 M |
$4.12 M |
Cost of Revenue |
$3.61 M
|
$3.45 M
|
$4.41 M
|
$3.09 M
|
Gross Profit |
$1.83 M
|
$1.68 M
|
$1.54 M
|
$1.02 M
|
Gross Profit Ratio |
0.34
|
0.33
|
0.26
|
0.25
|
Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
General & Administrative Expenses |
$2.78 M
|
$1.62 M
|
$1.10 M
|
$801.33 K
|
Selling & Marketing Expenses |
$206.31 K
|
$18.03 K
|
$36.19 K
|
$24.69 K
|
Selling, General & Administrative Expenses |
$2.99 M
|
$1.64 M
|
$1.14 M
|
$826.02 K
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$2.99 M
|
$1.64 M
|
$1.14 M
|
$826.02 K
|
Cost And Expenses |
$6.59 M
|
$5.09 M
|
$5.55 M
|
$3.92 M
|
Interest Income |
$6.95 K
|
$518.00
|
$21.00
|
$63.00
|
Interest Expense |
$778.66 K
|
$46.18 K
|
$77.76 K
|
$88.29 K
|
Depreciation & Amortization |
$206.26 K
|
$229.71 K
|
$303.94 K
|
$342.54 K
|
EBITDA |
$24.11 K |
$384.31 K |
$725.69 K |
$587.01 K |
EBITDA Ratio |
0
|
0.07
|
0.12
|
0.14
|
Operating Income Ratio |
-0.21
|
0.01
|
0.07
|
0.05
|
Total Other Income/Expenses Net |
$199.69 K
|
$66.18 K
|
-$54.72 K
|
-$42.57 K
|
Income Before Tax |
-$960.81 K
|
$108.42 K
|
$343.99 K
|
$156.18 K
|
Income Before Tax Ratio |
-0.18
|
0.02
|
0.06
|
0.04
|
Income Tax Expense |
-$486.71 K
|
$0.00
|
$208.14 K
|
$294.72 K
|
Net Income |
-$524.64 K
|
$130.19 K
|
$458.67 K
|
-$533.00
|
Net Income Ratio |
-0.1
|
0.03
|
0.08
|
-0
|
EPS |
0 |
0 |
0 |
0 |
EPS Diluted |
0 |
0 |
0 |
0 |
Weighted Average Shares Out |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Link |
|
|
|
|